Biocon Limited (NSE:BIOCON) filed its Q1 FY27 earnings call presentation with the NSE on 6 August 2026, pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The filing disclosed consolidated revenue from operations of Rs 4,336 crore and reported net profit of Rs 141 crore for the quarter.
Key Highlights
- Consolidated revenue from operations rose 10% year-on-year to Rs 4,336 crore in Q1 FY27, compared with Rs 3,942 crore in Q1 FY26.
- Reported net profit for Q1 FY27 stood at Rs 141 crore, up 355% year-on-year from Rs 31 crore in Q1 FY26, after accounting for exceptional items net of tax and minority interest.
- Biosimilars segment revenue grew 16% year-on-year to Rs 2,855 crore, with EBITDA margin at 25% and R&D spend at 7% of segment revenue.
- The Services segment reported a 16% year-on-year revenue decline to Rs 736 crore, impacted by lower offtake from a key biologics client and forex hedge losses.
About the Company
Biocon Limited (NSE:BIOCON), headquartered at Electronic City, Bengaluru, is a biopharmaceuticals company operating across three segments: Biosimilars, Generics, and Services. Founded in 1978 and listed on both the NSE and BSE, Biocon develops and markets insulin analogues, monoclonal antibodies, and small-molecule generic medicines across North America, Europe, and emerging markets. Its Services segment operates through subsidiary Syngene International Limited.
Announcement in Detail
The presentation filed under reference BIO/SECL/TG/2026-27/51 covers consolidated financial results for Q1 FY27. Total revenue reached Rs 4,391 crore, up 9% year-on-year. EBITDA stood at Rs 902 crore, representing a margin of 21%, unchanged year-on-year. Profit before tax before exceptional items was Rs 141 crore, a 24% year-on-year improvement. Net profit before exceptional items was Rs 145 crore, rising 245% from Rs 42 crore in Q1 FY26.
The Generics segment reported revenue of Rs 760 crore, up 21% year-on-year, with EBITDA turning positive at Rs 56 crore compared with a loss of Rs 35 crore in Q1 FY26. Generic liraglutide was cited as a key driver across multiple markets including the United States. The company also noted EMA approval for a second insulin drug product line in Malaysia, which it stated doubles capacity at that facility.
Impact on Investors
Investors will note that the filing shows a significant year-on-year recovery in reported net profit, from Rs 31 crore in Q1 FY26 to Rs 141 crore in Q1 FY27, driven partly by a reduction in exceptional item charges. The disclosed EBITDA margin of 21% was flat year-on-year but declined from 23% in Q4 FY26, which shareholders will observe reflects sequential pressure on profitability.
The filing indicates the Services segment, which contributed Rs 736 crore in revenue, saw EBITDA fall 48% year-on-year to Rs 116 crore. The company characterised FY27 as a transition year for this segment, with a return to sustainable growth described as targeted from FY28. The disclosed terms do not include specific numerical guidance for future quarters.
Sector / Market Context
India's pharmaceutical exports crossed USD 27 billion in FY26 according to the Pharmaceuticals Export Promotion Council of India, with biosimilars representing a growing share of that total. Global biosimilar market penetration continues to expand in the United States following policy measures to promote affordability and access, a backdrop against which Biocon's North America-led biosimilars growth is reported in the filing.